XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update dealnews2025-08-07T14:49:47+00:00August 7th, 2025|Endpoints News|
Chinese biotech Minghui raises $131M to advance its PD-1xVEGF bispecificnews2025-08-07T14:19:00+00:00August 7th, 2025|Endpoints News|
Scholar Rock expects September PDUFA for spinal muscular atrophy drug to stay unchanged despite CDMO woes news2025-08-07T13:16:44+00:00August 7th, 2025|Endpoints News|
Merck’s infant RSV antibody gets CDC’s recommendationnews2025-08-07T13:13:15+00:00August 7th, 2025|Endpoints News|
Translucent raises $7M for AI to analyze financial performancenews2025-08-07T12:00:33+00:00August 7th, 2025|Endpoints News|
FDA removes hold on Valneva’s chikungunya vaccine in those over 60, adjusts product labelnews2025-08-07T11:20:07+00:00August 7th, 2025|Endpoints News|
Lilly’s rise in revenue clouded by Phase 3 obesity pill readoutnews2025-08-07T11:11:05+00:00August 7th, 2025|Endpoints News|
Endpoints livestream: What we learned from Q2 earnings about China, tariffs and Trumpnews2025-08-07T11:00:53+00:00August 7th, 2025|Endpoints News|
Merck KGaA joins other drugmakers in considering direct-to-patient US sales news2025-08-07T10:52:40+00:00August 7th, 2025|Endpoints News|
Eli Lilly’s obesity pill is less effective than Novo Nordisk’s, pivotal data suggestnews2025-08-07T10:28:25+00:00August 7th, 2025|Endpoints News|
